Genetics of Myeloproliferative Neoplasms.
Calreticulin
Genetic alterations
Genetics
Genomics
JAK2
MPL
Myeloproliferative neoplasms
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
4
3
2022
Statut:
ppublish
Résumé
Myeloproliferative neoplasms are hematopoietic stem cell disorders based on somatic mutations in JAK2, calreticulin, or MPL activating JAK-STAT signaling. Modern sequencing efforts have revealed the genomic landscape of myeloproliferative neoplasms with additional genetic alterations mainly in epigenetic modifiers and splicing factors. High molecular risk mutations with adverse outcomes have been identified and clonal evolution may promote progression to fibrosis and acute myeloid leukemia. JAK2V617F is recurrently detected in clonal hematopoiesis of indeterminate potential with increased risk for vascular events. Insights into the genetics of myeloproliferative neoplasms has facilitated diagnosis and prognostication and poses novel candidates for targeted therapeutic intervention.
Identifiants
pubmed: 33641865
pii: S0889-8588(20)30153-2
doi: 10.1016/j.hoc.2020.12.002
pii:
doi:
Substances chimiques
Calreticulin
0
STAT Transcription Factors
0
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-236Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.